Greenwich LifeSciences Extends Lock-up of Directors and Officers to March 31, 2026
Greenwich LifeSciences (NASDAQ: GLSI) has announced an extension of the lock-up period for shares owned by company directors, officers, and pre-IPO investors until March 31, 2026. This extension represents approximately 66 months from the company's IPO date.
During this lock-up period, these insiders will be restricted from selling their common stock holdings unless modified by the Board of Directors. After the lock-up expiration, daily and periodic trading restrictions will still apply to these shares, subject to Board modification.
The company is currently conducting the Phase III FLAMINGO-01 clinical trial of GLSI-100, an immunotherapy designed to prevent breast cancer recurrences.
Greenwich LifeSciences (NASDAQ: GLSI) ha annunciato un'estensione del periodo di lock-up per le azioni detenute dai direttori, funzionari e investitori pre-IPO fino al 31 marzo 2026. Questa estensione rappresenta circa 66 mesi dalla data di IPO della società.
Durante questo periodo di lock-up, questi insider saranno limitati dalla vendita delle loro azioni ordinarie, a meno che non venga modificato dal Consiglio di Amministrazione. Dopo la scadenza del lock-up, continueranno ad applicarsi restrizioni giornaliere e periodiche per queste azioni, soggette a modifiche del Consiglio.
Attualmente, la società sta conducendo il trial clinico di Fase III FLAMINGO-01 di GLSI-100, un'immunoterapia progettata per prevenire le recidive del cancro al seno.
Greenwich LifeSciences (NASDAQ: GLSI) ha anunciado una extensión del período de lock-up para las acciones en poder de los directores, funcionarios e inversores pre-IPO hasta el 31 de marzo de 2026. Esta extensión representa aproximadamente 66 meses desde la fecha de la IPO de la empresa.
Durante este período de lock-up, estos insiders estarán restringidos de vender sus acciones ordinarias, a menos que el Consejo de Administración lo modifique. Después de la expiración del lock-up, seguirán aplicándose restricciones comerciales diarias y periódicas a estas acciones, sujetas a modificaciones del Consejo.
Actualmente, la empresa está llevando a cabo el ensayo clínico de Fase III FLAMINGO-01 de GLSI-100, una inmunoterapia diseñada para prevenir las recurrencias del cáncer de mama.
그리니치 라이프사이언스(Greenwich LifeSciences) (NASDAQ: GLSI)는 회사 이사, 임원 및 상장 전 투자자가 보유한 주식의 잠금 해제 기간을 2026년 3월 31일까지 연장한다고 발표했습니다. 이 연장은 회사의 IPO 날짜로부터 약 66개월을 나타냅니다.
이 잠금 해제 기간 동안, 이러한 내부자는 이사회의 수정이 없는 한 보통주를 판매하는 것이 제한됩니다. 잠금 해제 만료 후에도 이러한 주식에 대해서는 이사회의 수정에 따라 일일 및 정기적인 거래 제한이 여전히 적용됩니다.
회사는 현재 유방암 재발을 방지하기 위해 설계된 면역 요법인 GLSI-100의 3상 FLAMINGO-01 임상 시험을 진행하고 있습니다.
Greenwich LifeSciences (NASDAQ: GLSI) a annoncé une extension de la période de verrouillage pour les actions détenues par les directeurs, les responsables et les investisseurs pré-IPO jusqu'au 31 mars 2026. Cette extension représente environ 66 mois à partir de la date d'introduction en bourse de l'entreprise.
Au cours de cette période de verrouillage, ces initiés seront restreints dans la vente de leurs actions ordinaires, sauf si cela est modifié par le Conseil d'Administration. Après l'expiration du verrouillage, des restrictions de trading quotidiennes et périodiques s'appliqueront toujours à ces actions, sous réserve de modifications par le Conseil.
L'entreprise mène actuellement l'
Greenwich LifeSciences (NASDAQ: GLSI) hat eine Verlängerung der Lock-up-Periode für Aktien, die von Unternehmensdirektoren, -beamten und Pre-IPO-Investoren gehalten werden, bis zum 31. März 2026 angekündigt. Diese Verlängerung entspricht etwa 66 Monaten ab dem Datum des Börsengangs des Unternehmens.
Während dieser Lock-up-Periode sind diese Insider daran gehindert, ihre Stammaktien zu verkaufen, es sei denn, der Vorstand ändert dies. Nach Ablauf der Lock-up-Periode gelten weiterhin tägliche und periodische Handelsbeschränkungen für diese Aktien, vorbehaltlich der Änderungen durch den Vorstand.
Das Unternehmen führt derzeit die Phase-III-Studie FLAMINGO-01 zu GLSI-100 durch, einer Immuntherapie, die entwickelt wurde, um Rückfälle von Brustkrebs zu verhindern.
- Extended insider lock-up period demonstrates management's long-term commitment
- Lock-up extension helps prevent potential share price pressure from insider selling
- None.
STAFFORD, Texas, March 27, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that its Board of Directors has extended the lock-up of the shares owned by the Company's directors, officers, and existing pre-IPO investors to March 31, 2026 which is approximately 66 months from date of the Company's IPO. During this period, current officers, directors and certain shareholders will not be able to sell their shares of the Company's common stock unless otherwise modified by the Board of Directors. After March 31, 2026, the quantity of these locked-up shares that can be sold daily and over various periods of time will be restricted unless otherwise modified by the Board of Directors.
About FLAMINGO-01 and GLSI-100
FLAMINGO-01 (NCT05232916) is a Phase III clinical trial designed to evaluate the safety and efficacy of GLSI-100 (GP2 + GM-CSF) in HER2 positive breast cancer patients who had residual disease or high-risk pathologic complete response at surgery and who have completed both neoadjuvant and postoperative adjuvant trastuzumab based treatment. The trial is led by Baylor College of Medicine and currently includes US clinical sites from university-based hospitals and cooperative networks with plans to expand into Europe and to open up to 150 sites globally. In the double-blinded arms of the Phase III trial, approximately 500 HLA-A*02 patients will be randomized to GLSI-100 or placebo, and up to 250 patients of other HLA types will be treated with GLSI-100 in a third arm. The trial has been designed to detect a hazard ratio of 0.3 in invasive breast cancer-free survival, where 28 events will be required. An interim analysis for superiority and futility will be conducted when at least half of those events, 14, have occurred. This sample size provides
For more information on FLAMINGO-01, please visit the Company's website here and clinicaltrials.gov here. Contact information and an interactive map of the majority of participating clinical sites can be viewed under the "Contacts and Locations" section. Please note that the interactive map is not viewable on mobile screens. Related questions and participation interest can be emailed to: flamingo-01@greenwichlifesciences.com
About Breast Cancer and HER2/neu Positivity
One in eight U.S. women will develop invasive breast cancer over her lifetime, with approximately 300,000 new breast cancer patients and 4 million breast cancer survivors. HER2 (human epidermal growth factor receptor 2) protein is a cell surface receptor protein that is expressed in a variety of common cancers, including in
About Greenwich LifeSciences, Inc.
Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2 protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in
Forward-Looking Statement Disclaimer
Statements in this press release contain "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Greenwich LifeSciences Inc.'s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including statements regarding the intended use of net proceeds from the public offering; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section entitled "Risk Factors" in Greenwich LifeSciences' Annual Report on Form 10-K for the year ended December 31, 2023 and other periodic reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Greenwich LifeSciences, Inc. undertakes no duty to update such information except as required under applicable law.
Company Contact
Snehal Patel
Investor Relations
Office: (832) 819-3232
Email: info@greenwichlifesciences.com
Investor & Public Relations Contact for Greenwich LifeSciences
Dave Gentry
RedChip Companies Inc.
Office: 1-800-RED CHIP (733 2447)
Email: dave@redchip.com
FAQ
When does Greenwich LifeSciences' (GLSI) extended insider lock-up period end?
What trading restrictions apply to GLSI insiders after March 31, 2026?
Who is affected by Greenwich LifeSciences' (GLSI) lock-up extension?
What is Greenwich LifeSciences' (GLSI) main clinical trial focus?
